LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

FDA Approves Use of New Zika Assay to Screen Blood Supply

By LabMedica International staff writers
Posted on 16 Aug 2016
Print article
Image: A Zika virus capsid, colored per chains (Photo courtesy of Manuel Almagro Rivas / Wikimedia).
Image: A Zika virus capsid, colored per chains (Photo courtesy of Manuel Almagro Rivas / Wikimedia).
The US Food & Drug Administration (FDA) has approved the use of a new Zika virus assay to screen the USA blood supply under its Investigational New Drug (IND) study protocol. Blood banks will use the test on an automated nucleic acids technology (NAT) platform to screen donated blood in potential endemic areas.

The Procleix Zika virus assay, co-developed by leading blood safety partners Hologic, Inc. (Marlborough, MA, USA) and Grifols (Emeryville, CA, USA), will be used on the automated Procleix Panther system. Procleix Panther automates all aspects of NAT-based blood screening on a single, integrated platform. It eliminates the need for batch processing and combines walk-away freedom with intuitive design for ease of use. The system has received regulatory approvals in countries around the world, and is in development for use in the US.

Prominent blood centers will use the assay to screen donated blood collected in potential endemic areas of the southern US, and may expand testing to other areas of the U.S. if the virus continues to spread.

"The American Red Cross is pleased to participate in the Procleix Zika Virus assay investigational study, which will allow us to begin blood donor testing for Zika virus early this summer in areas most likely to have local mosquito transmission of the virus," said Susan Stramer, PhD, vice president, Scientific Affairs, American Red Cross, "Working together, we remain committed to ensuring the safety and availability of the US blood supply for patients in need."

"Zika virus is a rapidly growing threat to public health," said Tom West, division president, Diagnostic Solutions, Hologic, the “announcement demonstrates our ability to quickly develop molecular diagnostics in response to new and emerging pathogens." "As a global leader in Transfusion Medicine," said Carsten Schroeder, president, Grifols Diagnostic Division, "Grifols is proud to serve blood banks and healthcare professionals working around the world to ensure patients receive safe blood transfusions."

Related Links:
Hologic
Grifols
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.